CRISPR editing of HPFH3 genotype induces γ-globin expression and reverses sickle cell disease and β-thalassemia phenotypes
Collectively, our preclinical findings suggest that the generation of the HPFH3 genotype has the potential to significantly enhance HbF levels, offering a promising universal therapeutic strategy for treating both SCD and β-thalassemia.
Institutions
- Institute of Genomics and Integrative Biology (IN)
- Rajiv Gandhi Cancer Institute and Research Centre (IN)
- Regional Centre for Biotechnology (IN)
- RIKEN BioResource Research Center (JP)
- Cell Medica (Switzerland) (CH)
- Indian Institute of Technology Kanpur (IN)
- Academy of Scientific and Innovative Research (IN)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2025-12-21
- DOI
- https://doi.org/10.1186/s13287-025-04582-1
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00